Effect of gonadotropin-releasing hormone agonist treatment upon angiogenesis in uterine leiomyoma

被引:10
|
作者
Abulafia, O
Kleinhaus, K
Levi, G
Lee, YC
Sherer, DM
机构
[1] SUNY Hlth Sci Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Brooklyn, NY 11203 USA
[2] SUNY Hlth Sci Ctr, Dept Pathol, Brooklyn, NY 11203 USA
[3] Maimonides Hosp, Brooklyn, NY 11219 USA
[4] Columbia Univ Coll Phys & Surg, St Lukes Roosevelt Hosp Ctr, Dept Obstet & Gynecol, New York, NY 10032 USA
关键词
angiogenesis; uterine leiomyoma; gonadotropin-releasing hormone agonist therapy;
D O I
10.1159/000052953
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To assess the effect of gonadotropin-releasing hormone (GnRH)agonist treatment upon angiogenesis in uterine leiomyomata. Methods: Uterine leiomyomata specimens of 49 consecutive patients who underwent myomectomy or hysterectomy following presurgical treatment with (n = 23) and without (n = 26) GnRH agonist were stained immunohistochemically with antibody to factor VIII-related antigen. For each subject, age, parity, number of Lupron treatments, leiomyoma size (cm), and mean microvessel counts calculated from three fields (x400) were recorded. Differences in patient age, parity, microvessel counts and leiomyoma size between GnRH agonist treated and untreated patients were tested by unpaired Student's t test. Differences among the various number of doses were tested by one-way ANOVA, with Bonferonni and Neuman-Keuls post hoc tests between specific dose-number groups. The relationship between microvessel counts and leiomyoma size was tested by Pearson correlation test. Multivariate stepwise regression tested the relationship between the number of Lupron doses and microvessel counts, correcting for age, parity, and leiomyoma size. p < 0.05 was considered significant. Results: Patient age and parity were similar in GnRH treated and untreated patients (mean 43.3 <plus/minus> 6.6 versus 43.9 +/- 7.5 years and median 2 (range 0-7) versus 1 (range 0-5), p = 0.78 and p = 0.45, respectively). Microvessel counts of leiomyomata specimens treated presurgically with GnRH agonist therapy (median 22.7, range 6.7-65.7) were not significantly different from microvessel counts of specimens without presurgical GnRH agonist treatment (median 19.8, range 6-53; p = 0.77). No correlation between leiomyoma size and microvessel counts was noted (r = 0.06, P = 0.7). Conclusion: Angiogenesis as assessed by microvessel counts in surgically removed leiomyomata is not affected by presurgical medical management with GnRH agonist therapy. Copyright (C) 2001 S. Karger AG, Basel.
引用
收藏
页码:108 / 113
页数:6
相关论文
共 50 条
  • [21] Morphometric and electron microscopic analyses of the effect of gonadotropin-releasing hormone agonist treatment on arteriole size in uterine leiomyomas
    Kalir, T
    Wu, HS
    Gordon, RE
    Gil, J
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2000, 124 (09) : 1295 - 1298
  • [22] Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropin-releasing hormone agonist therapy
    Mizutani, T
    Sugihara, A
    Honma, H
    Komura, H
    Nakamuro, K
    Terada, N
    GYNECOLOGICAL ENDOCRINOLOGY, 2005, 20 (02) : 80 - 83
  • [23] Resolution of Uterine Arteriovenous Malformation and Successful Pregnancy After Treatment With a Gonadotropin-Releasing Hormone Agonist
    Nonaka, Taro
    Yahata, Tetsuro
    Kashima, Katsunori
    Tanaka, Kenichi
    OBSTETRICS AND GYNECOLOGY, 2011, 117 (02): : 452 - 455
  • [24] Gonadotropin-releasing hormone agonist treatment for endometriosis of the rectovaginal septum
    Fedele, L
    Bianchi, S
    Zanconato, G
    Tozzi, L
    Raffaelli, R
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2000, 183 (06) : 1462 - 1467
  • [25] TREATMENT OF ENDOMETRIOSIS WITH A POTENT AGONIST OF GONADOTROPIN-RELEASING HORMONE (NAFARELIN)
    SCHRIOCK, E
    MONROE, SE
    HENZL, M
    JAFFE, RB
    FERTILITY AND STERILITY, 1985, 44 (05) : 583 - 588
  • [26] EFFICACY OF GONADOTROPIN-RELEASING HORMONE AGONIST (BUSERELIN) IN THE TREATMENT OF ENDOMETRIOSIS
    RONNBERG, L
    KOSKIMIES, A
    LAATIKAINEN, T
    RANTA, T
    SAASTAMOINEN, J
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1989, 68 (01) : 49 - 53
  • [27] Gonadotropin-releasing hormone agonist increases expression of osmotic response genes in leiomyoma cells
    McCarthy-Keith, Desiree M.
    Malik, Minnie
    Britten, Joy
    Segars, James
    Catherino, William H.
    FERTILITY AND STERILITY, 2011, 95 (07) : 2383 - 2387
  • [28] Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Uterine Leiomyomas
    Neblett II, Michael F.
    Stewart, Elizabeth A.
    OBSTETRICS AND GYNECOLOGY, 2023, 141 (05): : 901 - 910
  • [29] EFFECTS OF GONADOTROPIN-RELEASING HORMONE AGONIST ON UTERINE FIBROIDS AND BONE-DENSITY
    BIANCHI, G
    COSTANTINI, S
    ANSERINI, P
    ROVETTA, G
    MONTEFORTE, P
    MENADA, MV
    FAGA, L
    DECECCO, L
    MATURITAS, 1989, 11 (03) : 179 - 185
  • [30] CONVERSION OF A GONADOTROPIN-RELEASING HORMONE ANTAGONIST TO AN AGONIST
    CONN, PM
    ROGERS, DC
    STEWART, JM
    NIEDEL, J
    SHEFFIELD, T
    NATURE, 1982, 296 (5858) : 653 - 655